telmisartan + amlodipine + atorvastatin

Telmisartan + amlodipine + atorvastatin is a fixed-dose combination of three pharmaceutical agents used primarily for the management of patients with both hypertension and dyslipidemia. Telmisartan is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, leading to vasodilation. Amlodipine is a calcium channel blocker (CCB) that inhibits calcium influx into vascular smooth muscle and cardiac muscle, resulting in relaxation of blood vessels and reduced cardiac workload. Atorvastatin is an HMG-CoA reductase inhibitor (statin) that reduces cholesterol synthesis in the liver, thereby lowering LDL cholesterol levels and overall cardiovascular risk. This triple combination targets multiple cardiovascular risk factors simultaneously—hypertension via ARB and CCB mechanisms, and hyperlipidemia via statin therapy—making it suitable for patients at high risk for cardiovascular events who require both antihypertensive and lipid-lowering treatment[2][3][4].